Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy, ctDNA Dynamics Provide Prognostic Value Beyond pCR By Ogkologos - July 28, 2025 652 0 Facebook Twitter Google+ Pinterest WhatsApp Final results from the IMpassion031 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Ifosfamide May Be Treatment of Choice for Some People with Ewing... July 8, 2022 FDA Approves Pembrolizumab for Cutaneous Squamous Cell Carcinoma June 26, 2020 New Study Finds Dogs Can Sniff Out Lung Cancer — And... April 10, 2019 Distinct and Overlapping Pathways Contribute to the Efficacy of Nivolumab-Based Regimens... March 26, 2025 Load more HOT NEWS COVID-19: “We’re having to rebuild and adapt because of coronavirus” How Clinical Trials Can Lead to Life-Saving Treatment: The TAPUR Trial... Metastatic Colorectal Cancer May Spread Early in the Disease, Study Finds Percentage of Cancer Patients Who Are Eligible for and Respond to...
